

Foundayo (orforglipron)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Initial: 6 months Continuation: 1 year

Medications	Quantity Limit
Foundayo (orforglipron)	May be subject to quantity limit

APPROVAL CRITERIA

Initial requests for Foundayo (orforglipron) for chronic weight management for adults may be approved if the following criteria are met:

- I. Individual is 18 years of age or older and one of the following:
 - A. Documentation* is provided that individual has a BMI of 30 kg/m² or greater (**documentation of BMI is required within 90 days of the request*); **OR**
 - B. Documentation* is provided that individual has a BMI of greater than or equal to 27 kg/m² and at least one of the following weight-related comorbid conditions (**documentation of BMI is required within 90 days of the request*):
 1. Hypertension defined as treated hypertension or with systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure ≥80 mmHg; **OR**
 2. Type II Diabetes Mellitus; **OR**
 3. Dyslipidemia defined as treated dyslipidemia or has low-density lipoprotein (LDL) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7 mmol/L), or high-density lipoprotein (HDL) <40 mg/dL (1.0 mmol/L) for men or HDL <50 mg/dL (1.3 mmol/L) for women; **OR**
 4. Obstructive sleep apnea (as a result of having a BMI of 27 kg/m² or greater); **OR**
 5. Cardiovascular disease (example includes ischemic cardiovascular disease, New York Heart Association (NYHA) defined heart failure);

AND

- II. Individual has tried but was unsuccessful losing weight through a healthcare provider supervised comprehensive lifestyle program for at least 6 months, prior to request for drug therapy, that included ALL the following:
 - A. A calorie deficit of approximately 30% (i.e. 500 kcals relative to their estimated total energy expenditure) in calories per day has been achieved by the individual for at least 6 months; **AND**
 - B. An exercise goal of completing at least 150 minutes of exercise per week has been achieved for at least 6 months; **OR**

1. Exercise requirements cannot be met due to clinical limitations (including but not limited to cardiovascular conditions, physical limitations, fall risk); **AND**
- C. Individual was unable to achieve at least a 5% weight reduction with calorie deficit goals, exercise goals, and behavior therapy;
OR
- III. Individual has a diagnosis of New York Heart Association Class III or IV heart failure;
OR
- IV. Individual has moderate to severe obstructive sleep apnea with an apnea-hypopnea index (AHI) score of greater than or equal to 15;
OR
- V. Individual has a BMI of 40 kg/m² or greater;

AND

- VI. Individual is currently maintained on a healthcare provider supervised lifestyle program that includes all of the following:
 - A. An individualized calculated calorie deficit of approximately 30% (or 500 kcals relative to their estimated total energy expenditure) in calories per day (AACE 2016/AGA 2022); **AND**
 - B. Completing at least 150 minutes of exercise per week (AACE 2016/AGA 2022); **OR**
 1. Exercise requirements cannot be met due to clinical limitations (including but not limited to cardiovascular conditions, physical limitations, fall risk);

AND

- VII. Individual is NOT receiving two or more medications for weight loss at the same time;

AND

- VIII. Healthcare provider has consulted with individual regarding risks (including but not limited to adverse drug events), benefits, realistic expectations associated with the requested drug and the need for long-term follow-up and adherence to behavior modifications.

Continuation requests for Foundayo (orforglipron) for chronic weight management for adults may be approved if ALL of the following criteria are met:

- I. Individual is 18 years of age or older and one of the following:
 - A. Documentation is provided that at initiation of therapy, individual had a BMI of 30 kg/m² or greater; **OR**
 - B. Documentation is provided that at initiation of therapy, individual had a BMI of greater than or equal to 27 kg/m² and at least one of the following weight-related comorbid conditions:

1. Hypertension defined as treated hypertension or with systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg; **OR**
2. Type II Diabetes Mellitus; **OR**
3. Dyslipidemia defined as treated dyslipidemia or has low-density lipoprotein (LDL) ≥ 160 mg/dL (4.1 mmol/L) or triglycerides ≥ 150 mg/dL (1.7 mmol/L), or high-density lipoprotein (HDL) < 40 mg/dL (1.0 mmol/L) for men or HDL < 50 mg/dL (1.3 mmol/L) for women; **OR**
4. Obstructive sleep apnea (as a result of having a BMI of 27 kg/m² or greater); **OR**
5. Cardiovascular disease (example includes ischemic cardiovascular disease, New York Heart Association (NYHA) defined heart failure);

AND

- II. Documentation[^] is provided that individual has achieved/maintained an initial 5% weight loss (*^documentation showing the achieved/maintained 5% weight loss is required within 90 days of each continuation/subsequent request*); **AND**
- III. Individual continues to be engaged in a comprehensive lifestyle program which includes:
 - A. Individual is currently maintained on an individualized calculated calorie deficit of approximately 30% (or 500 kcals relative to their estimated total energy expenditure) in calories per day (AACE 2016/AGA 2022); **AND**
 - B. Individual is currently maintaining 150 minutes of exercise per week (AACE 2016/AGA 2022); **OR**
 1. Exercise requirements cannot be met due to clinical limitations (including but not limited to cardiovascular conditions, physical limitations, fall risk); **AND**
- IV. Individual is NOT receiving two or more medications for weight loss at the same time; **AND**
- V. Healthcare provider has consulted with individual regarding risks (including but not limited to adverse drug events), benefits realistic expectations associated with the requested drug and the need for long-term follow-up and adherence to behavior modifications.

Requests for Foundayo (orforglipron) for chronic weight management may not be approved for any of the following:

- I. Individual has a BMI of less than 18.5 kg/m² (CDC 2024); **OR**
- II. Individual is using in combination with another GLP-1 receptor agonist [including but not limited to semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda, Victoza)]; **OR**
- III. Individual with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a personal or family history of medullary thyroid carcinoma (MTC).

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
2. Merative™ Micromedex® DRUGDEX® (electronic version). Merative, Ann Arbor, Michigan, USA.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2026; Updated periodically.
4. Apovian, Caroline M., et al. "Pharmacological management of obesity: an endocrine society clinical practice guideline." *J Clin Endocrinol Metab*, Feb 2015, 100(2):342-362.
5. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA*. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.
6. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update [published correction appears in *Endocr Pract*. 2023 Jan;29(1):80-81]. *Endocr Pract*. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002.
7. Curry S. US Preventative Services Task Force Recommendation Statement. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults. *JAMA* 2018; 320(11): 1163-1171.
8. ElSayed NA, Aleppo G, Aroda VR, et al. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023;46(Suppl 1):S128-S139. doi:10.2337/dc23-S008.
9. Garvey WT, Mechanick JL, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract* 2016; 22 (Suppl 3):1-203
10. Grunwald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., Davitkov, P., & AGA Clinical Guidelines Committee (2022). AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. *Gastroenterology*, 163(5), 1198–1225. <https://doi.org/10.1053/j.gastro.2022.08.045>.
11. Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. *Lancet*. 2026;406(10522):2927-2944. doi:10.1016/S0140-6736(25)02165-8.
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.
13. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in *Circulation*. 2014 Jun 24;129(25 Suppl 2):S139-40]. *Circulation*. 2014;129(25 Suppl 2):S102-S138. doi:10.1161/01.cir.0000437739.71477.ee.
14. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. *N Engl J Med*. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774.
15. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update. *Endocr Pract*. 2025;31(11):1351-1394. doi:10.1016/j.eprac.2025.07.017.
16. Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. *JAMA*. 2026;335(5):434-438. doi:10.1001/jama.2025.24288.
17. Alexander L, Purnell JQ, Burrige K, et al. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach. *Obesity (Silver Spring)*. 2026;34(4):851-870. doi:10.1002/oby.70164.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.